Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: genetics – Page 2

Scientists Use Engineered Cells to Combat Aging in Primates

As we age, our bodies gradually lose their ability to repair and regenerate. Stem cells diminish, making it increasingly difficult for tissues to heal and maintain balance. This reduction in stem cells is a hallmark of aging and a key driver of age-related diseases. Scientists have long debated whether this decline is the root cause of aging or a side effect. Efforts to use stem cell transplants to reverse aging have faced many challenges, such as ensuring the cells survive and integrate into the body without causing serious side effects, like tumors.

In a recent study published in Cell, researchers from the Chinese Academy of Sciences and Capital Medical University introduced a new type of human stem cell called senescence-resistant mesenchymal progenitor cells (SRCs) by reprogramming the genetic pathways associated with longevity. These cells, which resist aging and stress without developing tumors, were tested on elderly crab-eating macaques, which share physiological similarities with humans in their 60s and 70s.

The research team conducted a 44-week experiment on these macaques. The macaques received biweekly intravenous injections of SRCs, with a dosage of 2×106 cells per kilogram of body weight. The researchers found no adverse effects among the macaques. Detailed assessments confirmed that the transplanted cells did not cause tissue damage or tumors.

The researchers discovered that SRCs triggered a multi-system rejuvenation, reversing key markers of aging across 10 major physiological systems and 61 different tissue types. The treated macaques exhibited improved cognitive function, and tissue analyses indicated a reduction in age-related degenerative conditions such as brain atrophy, osteoporosis, fibrosis, and lipid buildup. 👍

Estimating Polar Bear (Ursus maritimus) Age Based on an Epigenetic DNA Methylation Clock

We developed a robust epigenetic clock to estimate age from two wild polar bear subpopulations using blood samples. There was a correlation between epigenetic (DNAm) and chronological age throughout the polar bear lifespan. Polar bears in the wild have a lifespan of approximately 25 years (Rode and Stirling 2018), thus the clock estimates age to ±3% of the polar bear lifespan, although we caution that age estimates may be less accurate for older individuals. Advantages to this method include obtaining more accurate age estimates compared to cementum annuli-derived ages and leveraging samples likely already routinely collected (e.g., blood, tissue) during capture, as opposed to pulling teeth. Further, archived samples or previously extracted DNA may be used for DNAm analysis, extending the value of existing samples and saving money on DNA extraction costs. Our results complement other polar bear clocks (Newediuk et al. 2024, 2025) and provide additional support for the use of DNAm methods to estimate the age of wild mammals (De Paoli-Iseppi et al. 2017).

Our DNAm method estimates polar bear age with a MAE of 0.75 years. In contrast, accuracy of cementum annuli for aging polar bears to within 1 year of actual age has ranged from 32% to 75% (Calvert and Ramsay 1998 ; Christensen-Dalsgaard et al. 2010 ; Hensel and Sorensen 1980). Cementum annuli age estimates are less accurate when made by less experienced observers (Christensen-Dalsgaard et al. 2010 ; Hensel and Sorensen 1980 ; McLaughlin et al. 1990) and can vary between laboratories by 10 years (Christensen-Dalsgaard et al. 2010). For example, in one lab, multiple female polar bears were aged at ~10 years, while a second laboratory aged them at 20 years old (Christensen-Dalsgaard et al. 2010). Our method removes these sources of error. We do, however, acknowledge a potential source of technical error, given that all but three of the tooth-aged samples were run on one plate, and the majority of our known age samples were run on another plate.

ER-100: The “Miracle Cure” For Aging? | Aubrey de Grey

The ER-100 drug candidate reverses aging in mice, and David Sinclair says human trials start soon. Is this a magic pill for aging? Dr. Aubrey de Grey discusses the latest advances in life-extension research.

Our story begins on X, where user “rand_longevity” wrote, “Aging will be reversible in humans within 8 years”, to which Dr. David Sinclair replied, “8 years? After successful non-human primate trials, human age reversal trials are set to begin in 6 months”, later naming the ER-100 drug candidate.

Life Biosciences ER-100 drug candidate leverages partial epigenetic programming using 3 of the 4 Yamanaka factors to promote cellular rejuvenation to a younger state without the loss of cell identity. They believe this will help prevent or reverse age-related diseases at a root level — but they’re not the only organization pursuing life-extension research.

Dr. de Grey’s own research has focused primarily on accumulated side effects from metabolism, embodied in the title of his 1999 book, “The Mitochondrial Free Radical Theory of Aging”.

Dr. de Grey is well-known as one of the top gerontology and life-extension scientists in the world, and his own work has also been successful in extending the lifespan of lab animals. In this program, he discusses his work and some of the key elements of living a longer, healthier life.

DISCLAIMER: This program is a discussion is about ongoing scientific research, and is NOT providing medical advice. Please consult your doctor before starting any supplements, beginning an exercise routine, or undertaking lifestyle changes.

Continue reading “ER-100: The “Miracle Cure” For Aging? | Aubrey de Grey” | >

Sugar layer on beta cells prevents immune system from causing type 1 diabetes

Scientific breakthroughs in one disease don’t always shed light on treating other diseases. But that’s been the surprising journey of one Mayo Clinic research team. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1 diabetes, once known as juvenile diabetes.

Type 1 diabetes is a chronic autoimmune condition in which the immune system errantly attacks that produce insulin. The disease is caused by genetic and other factors and affects an estimated 1.3 million people in the U.S.

In their studies, the Mayo Clinic researchers took a cancer mechanism and turned it on its head. Cancer cells use a variety of methods to evade , including coating themselves in a known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it’s possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells.

Scientists shrink the genetic code of E. coli to contain only 57 of its usual 64 codons

The DNA of nearly all life on Earth contains many redundancies, and scientists have long wondered whether these redundancies served a purpose or if they were just leftovers from evolutionary processes. Both DNA and RNA contain codons, which are sequences of three nucleotides that either provide information about how to form a protein with a specific amino acid or tell the cell to stop (a stop signal) during protein synthesis.

Lipid nanoparticle stereochemistry shapes mRNA delivery safety and efficacy, study reveals

A team from the Max-Planck-Institut für Kohlenforschung, Hokkaido University, and Osaka University has discovered that subtle differences in molecular structure can have a major impact on the performance of mRNA-based drugs. Their findings, published in the Journal of the American Chemical Society, open the door to the development of safer and more effective vaccines and therapies.

To deliver therapeutic nucleic acids like mRNA into cells, scientists rely on (LNPs)—tiny, fat-based carriers that protect fragile genetic material, enabling it to survive in the body and reach target cells. A key component of these LNPs are ionizable lipids, which help mRNA enter cells and then release it effectively. One such lipid, ALC-315, was notably used in the Pfizer/BioNTech COVID-19 vaccine, a medical breakthrough that played a critical role in controlling the global pandemic.

PIK3CA inhibitor treatment for metastatic scrotal extramammary Paget’s disease: a case report and literature review

Background: Extramammary Paget’s disease (EMPD) is a rare intraepithelial adenocarcinoma that occurs in the genitals, axilla, and anus, where apocrine sweat glands are abundant. This disease is mainly characterized by localized lesions and rare distant metastasis. Scrotal Paget’s disease is a rare type of EMPD, and there is no standard treatment for metastatic EMPD.

Case Description: Here, we reported the genetic results of a patient with a PIK3CA gene mutation in scrotal Paget’s disease who developed multiple metastases to the lymph nodes, liver, and bones during adjuvant radiotherapy, as well as the results of treatment with a PIK3CA inhibitor. The latest advances in this field were also summarized. The treatment response was evaluated as stable disease (SD) after 6 courses of docetaxel plus tegafur (DS regimen) chemotherapy. Then, a second-line treatment, a PIK3CA inhibitor, WX390, was administered with tolerable toxicity. There was a treatment-induced increase in blood glucose level during treatment, and insulin was administrated with good control. The progression-free survival (PFS) was 3.9 months and the overall survival (OS) was 16 months.

Conclusions: PIK3CA is a commonly mutated gene in EMPD. To the best of our knowledge, this is the first case report of a PIK3CA inhibitor for the treatment of primary metastatic EMPD, and the treatment efficacy was good. PIK3CA inhibitors may be promising for the treatment of metastatic EMPD in the future.

EpInflammAge: Epigenetic-Inflammatory Clock for Disease-Associated Biological Aging Based on Deep Learning

We present EpInflammAge, an explainable deep learning tool that integrates epigenetic and inflammatory markers to create a highly accurate, disease-sensitive biological age predictor. This novel approach bridges two key hallmarks of aging—epigenetic alterations and immunosenescence. First, epigenetic and inflammatory data from the same participants was used for AI models predicting levels of 24 cytokines from blood DNA methylation. Second, open-source epigenetic data (25 thousand samples) was used for generating synthetic inflammatory biomarkers and training an age estimation model. Using state-of-the-art deep neural networks optimized for tabular data analysis, EpInflammAge achieves competitive performance metrics against 34 epigenetic clock models, including an overall mean absolute error of 7 years and a Pearson correlation coefficient of 0.85 in healthy controls, while demonstrating robust sensitivity across multiple disease categories. Explainable AI revealed the contribution of each feature to the age prediction. The sensitivity to multiple diseases due to combining inflammatory and epigenetic profiles is promising for both research and clinical applications. EpInflammAge is released as an easy-to-use web tool that generates the age estimates and levels of inflammatory parameters for methylation data, with the detailed report on the contribution of input variables to the model output for each sample.

RNA-seq outperforms DNA methods in detecting actionable cancer mutations

Hospital for Sick Children in Toronto researchers are reporting that targeted RNA sequencing can detect clinically actionable alterations in 87% of tumors and provide decisive findings where DNA-seq either fails, returns no variant, or is not informative.

Cancer treatments have seen tremendous improvements in recent years, in part due to highly specific targeting and .

DNA-based methods dominate molecular cancer diagnostics but struggle to detect and assess splice site consequences. RNA sequencing enables sensitive fusion detection and direct assessment of transcript-level disruption caused by splicing mutations.

Bacteria-based sensors deliver real-time detection of arsenite and cadmium in water

Researchers at Rice University have engineered E. coli to act as living multiplexed sensors, allowing these genetically modified cells to detect and respond to multiple environmental toxins simultaneously by converting their biological responses into readable electrical signals. This innovation opens the door to real-time, remote monitoring of water systems, pipelines and industrial sites with potential future applications in biocomputing.

A new study published in Nature Communications demonstrates an innovative method for the real-time, on-site detection of arsenite and cadmium at levels set by the Environmental Protection Agency.

This research, led by Xu Zhang, Marimikel Charrier and Caroline Ajo-Franklin, addresses a significant inefficiency in current bioelectronic sensors, which typically require dedicated communication channels for each target compound. The research team’s multiplexing strategy greatly enhances information throughput by leveraging bacteria’s innate sensitivity and adaptability within a self-powered platform.

/* */